A New Hope in the Fight Against Pancreatic Cancer
A revolutionary new test has been developed that could detect one of the deadliest forms of cancer years before a diagnosis is made. This breakthrough could save thousands of lives and change the way pancreatic cancer is treated.
Researchers at the Mayo Clinic in Minnesota have created an AI-assisted test called REDMOD, which is capable of identifying pancreatic cancer up to three years before a patient receives a formal diagnosis. The AI model was specifically designed to detect even the most subtle changes in tissue associated with pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer.
Conventional imaging techniques and human observation often struggle to detect these early signs, as they can be extremely difficult to spot. This makes pancreatic cancer particularly dangerous, as it tends to progress rapidly without noticeable symptoms in its early stages.
The Stealthy Nature of Pancreatic Cancer
Pancreatic cancer is often referred to as a “cancer that whispers” rather than shouts. In its early phases, the symptoms are vague and can easily be mistaken for other, less serious conditions. These may include:
- A dull ache in the back
- Intermittent indigestion
- Unexplained fatigue
- Subtle yellowing of the eyes or skin that comes and goes
By the time patients realize something is seriously wrong, the disease has often already advanced to a stage where treatment options are limited. In fact, around 80 percent of cases are diagnosed after the cancer has spread beyond the pancreas, making surgery – currently the only potential cure – no longer viable.
The survival rate for pancreatic cancer is alarmingly low. Overall, just 12 percent of patients live for five years after diagnosis, and many do not survive more than a year. Each year, approximately 67,000 Americans are diagnosed with the disease, and over 52,000 die from it.
How REDMOD Works
Now, researchers believe that the AI-assisted technology could detect the cancer at stage 0, when it is still treatable and the chances of survival are significantly higher. Dr Ajit Goenka, the study’s senior author and a Mayo Clinic radiologist, said: “The greatest barrier to saving lives from pancreatic cancer has been our inability to see the disease when it is still curable. This AI can now identify the signature of cancer from a normal-appearing pancreas, and it can do so reliably over time and across diverse clinical settings.”
The study, published in the journal Gut, used REDMOD on hundreds of CT scans from 219 patients who were initially deemed to show no evidence of disease. However, these patients were later diagnosed with pancreatic cancer. REDMOD was able to detect the ‘invisible’ signature of pre-clinical pancreatic cancer an average of 475 days before diagnosis.
In addition to its ability to detect cancer earlier, REDMOD outperformed radiologists in terms of sensitivity. It correctly identified cancer in 73 percent of cases, compared to 39 percent among radiologists. The AI model was also nearly three times as accurate as radiologists when detecting cases more than two years before diagnosis, achieving accuracy in 68 percent of cases compared to 23 percent.
Future Prospects and Challenges
While the researchers acknowledge that their patient set was not diverse enough, they believe that the results validate REDMOD as a fully automated AI framework capable of identifying the imaging signatures of stage 0 pancreatic ductal adenocarcinoma in a normal pancreas. They note that the model achieves this with substantial lead times and performance superior to expert radiologists.
They conclude: “While prospective validation is paramount to confirm clinical utility, the REDMOD framework represents a significant advance towards shifting the paradigm for sporadic [pancreatic ductal adenocarcinoma] from a late-stage symptomatic diagnosis to proactive pre-clinical interception, offering tangible hope for improving outcomes in this challenging disease.”
